[go: up one dir, main page]

WO2003006645A3 - Methode et composition permettant d'inhiber l'activite de l'heparanase - Google Patents

Methode et composition permettant d'inhiber l'activite de l'heparanase Download PDF

Info

Publication number
WO2003006645A3
WO2003006645A3 PCT/US2002/021773 US0221773W WO03006645A3 WO 2003006645 A3 WO2003006645 A3 WO 2003006645A3 US 0221773 W US0221773 W US 0221773W WO 03006645 A3 WO03006645 A3 WO 03006645A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogen
heparanase
composition
present
heparanase activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/021773
Other languages
English (en)
Other versions
WO2003006645A2 (fr
Inventor
Peter Bohlen
Daniel Hicklin
Paul Kussie
Yiwen Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone Systems Inc filed Critical ImClone Systems Inc
Priority to CA002453566A priority Critical patent/CA2453566A1/fr
Priority to JP2003512403A priority patent/JP2005521379A/ja
Priority to EP02763248A priority patent/EP1417304A4/fr
Priority to US10/483,858 priority patent/US20040247577A1/en
Publication of WO2003006645A2 publication Critical patent/WO2003006645A2/fr
Publication of WO2003006645A3 publication Critical patent/WO2003006645A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01166—Heparanase (3.2.1.166)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)

Abstract

L'invention concerne des méthodes permettant d'inhiber l'activité de l'héparanase et de traiter différents états par administration, à un animal, d'une quantité efficace d'un immunogène sollicitant une réponse immunitaire contre l'héparanase. Selon l'invention, l'immunogène est l'héparanase ou un fragment de celle-ci, cet immunogène étant, de préférence, une cellule présentant un antigène (APC), telle qu'une cellule dendritique (DC) affichant l'héparanase ou un fragment de celle-ci sur sa surface. L'invention concerne également des compositions contenant ledit immunogène.
PCT/US2002/021773 2001-07-13 2002-07-10 Methode et composition permettant d'inhiber l'activite de l'heparanase Ceased WO2003006645A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002453566A CA2453566A1 (fr) 2001-07-13 2002-07-10 Methode et composition permettant d'inhiber l'activite de l'heparanase
JP2003512403A JP2005521379A (ja) 2001-07-13 2002-07-10 ヘパラナーゼ活性を阻害するための方法及び組成物
EP02763248A EP1417304A4 (fr) 2001-07-13 2002-07-10 Methode et composition permettant d'inhiber l'activite de l'heparanase
US10/483,858 US20040247577A1 (en) 2001-07-13 2002-07-10 Method and composition for inhibiting heparanase activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30544601P 2001-07-13 2001-07-13
US60/305,446 2001-07-13
US35755302P 2002-02-15 2002-02-15
US60/357,553 2002-02-15

Publications (2)

Publication Number Publication Date
WO2003006645A2 WO2003006645A2 (fr) 2003-01-23
WO2003006645A3 true WO2003006645A3 (fr) 2003-07-24

Family

ID=26974593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/021773 Ceased WO2003006645A2 (fr) 2001-07-13 2002-07-10 Methode et composition permettant d'inhiber l'activite de l'heparanase

Country Status (4)

Country Link
EP (1) EP1417304A4 (fr)
JP (1) JP2005521379A (fr)
CA (1) CA2453566A1 (fr)
WO (1) WO2003006645A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1479764A1 (fr) 2003-05-19 2004-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptides derives de Heparanas pour la vaccination des patients cancereux
ES2251289B1 (es) * 2004-02-27 2007-07-01 Bioiberica, S.A. Nuevo uso terapeutico de un grupo de polisacaridos sulfatados.
KR101578342B1 (ko) * 2008-03-31 2015-12-16 가부시키가이샤 시세이도 주름을 방지 또는 개선하기 위한 경구, 주사, 피부 외용제 및 미용 방법
US20180110799A1 (en) * 2014-09-02 2018-04-26 The Children's Hospital Of Philadelphia Compositions and Methods for the Inhibition of Chondrogenesis
JP2023533383A (ja) * 2020-07-02 2023-08-02 アンスティテュ・フランセ・ドゥ・レシェルシェ・プール・レクスプローテシオン・ドゥ・ラ・メール （イエフエルウメール） 海洋性細菌性エキソポリサッカライド誘導体及びムコ多糖症の処置におけるその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242238B1 (en) * 1997-10-28 2001-06-05 The Australian National University Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968822A (en) * 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
WO2000052178A1 (fr) * 1999-03-01 2000-09-08 Insight Strategy & Marketing Ltd. Polynucleotide codant pour un polypeptide ayant une activite d'heparanase et expression de ce polynucleotide dans des cellules genetiquement modifiees
DE19955803A1 (de) * 1999-11-19 2001-05-23 Knoll Ag Verwendung von Heparanase-Inhibitoren zur Behandlung von Hersinsuffizienz

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242238B1 (en) * 1997-10-28 2001-06-05 The Australian National University Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1417304A4 *

Also Published As

Publication number Publication date
JP2005521379A (ja) 2005-07-21
WO2003006645A2 (fr) 2003-01-23
EP1417304A4 (fr) 2005-11-23
CA2453566A1 (fr) 2003-01-23
EP1417304A2 (fr) 2004-05-12

Similar Documents

Publication Publication Date Title
IN2006KO01346A (fr)
PL331802A1 (en) Substituted cyclic amines as metaloprotease inhibitors
DE69936102D1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
WO2003057698A3 (fr) Composes spiroazacycliques utilises comme modulateurs du recepteur de monoamine
WO2005016962A3 (fr) Compositions et techniques de traitement de maladies liees a l'immunite
CA2437844A1 (fr) Procede visant a accroitre les taux de leptine a l'aide de composes d'acide nicotinique
WO2003000200A3 (fr) ss-2'-OU 3'-HALONUCLEOSIDES
TWI265929B (en) Triazinyl derivatives for inhibiting the production of IL-12
IL162616A0 (en) Tetrahydroquinoline analogues as muscarinic agonists
WO2000077206A3 (fr) Promoteur du gene de la myostatine et methode pouvant inhiber l'activation dudit promoteur
AU2251901A (en) Methods and compounds for inhibiting MRP1
MXPA01003501A (es) Metodo para moderar el estres o tension de las plantas.
WO2004043456A8 (fr) Inhibiteurs d'absorption du cholesterol pour le traitement de la demyelination
AU9624198A (en) Quinoline and quinazoline derivatives having corticotropin releasing factor (crf) antagonist activity
WO2000000198A8 (fr) Derives de piperidine agissant sur les systemes lies a la serotonine
WO2002096420A3 (fr) Procede de traitement d'accidents nerveux entraines par une operation
WO2004032908A3 (fr) Methode d'inhibition de l'angiogenese
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
WO2003006645A3 (fr) Methode et composition permettant d'inhiber l'activite de l'heparanase
WO1993015112A3 (fr) COMPOSES ET PROCEDES D'INHIBITION DE LA FONCTION DE LA PROTEINE $g(b)
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
IL165220A0 (en) Novel compounds, their use and preparation
WO2000057908A3 (fr) Vaccin antiviral attenue du dengue de type 1
WO1999057278A3 (fr) Immunisation et traitement anti-infectieux
WO2000057904A3 (fr) Vaccin a base de virus de dengue-3 attenue

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003512403

Country of ref document: JP

Ref document number: 2453566

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002763248

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002763248

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10483858

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002763248

Country of ref document: EP